CervoMed's neflamapimod gets FDA Orphan Drug Designation for frontotemporal dementia

CervoMed Inc.

FDA granted Orphan Drug Designation for neflamapimod to treat frontotemporal dementia (FTD).
Designation recognizes scientific rationale; FTD currently has no approved treatment options.
CervoMed in discussions with clinical thought leaders to design a proof-of-principle FTD study.
Company on track to report topline data from RewinD-LB Phase 2b trial in DLB in December 2024.
Benefits include development assistance, tax credits, fee exemptions, and 7-year post-approval exclusivity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.